FACIT's Prospects Oncology Fund backs three
FACIT's Prospects Oncology Fund has provided seed capital to Ontario-based medical device and new therapeutic platform technologies. The recipients to secure this financing are Xpan Inc, a medical device startup; Dr. Igor Stagljar of the University of Toronto; and the Drug Discovery Program at the Ontario Institute for Cancer Research. Xpan Inc is developing surgical access ports that aim to increase safety and efficiency of minimally invasive surgeries. Dr. Stagljar is developing a system for detecting protein-protein interactions in real time for drug discovery applications while OICR's Drug Discovery Program is developing a platform targeting multiple members of the WD40 repeat domain family with small molecules. No financial terms were disclosed.
